Intel to use 'big data' to battle Parkinson's disease

Intel headquarters on January 16, 2014 in Santa Clara, California
Intel headquarters on January 16, 2014 in Santa Clara, California

US computing giant Intel announced Wednesday it was joining an effort to battle Parkinson's disease with new big data and wearable technologies to improve research and treatment.

Intel said it would work with the Michael J. Fox Foundation for Parkinson's Research—created by the "Back to the Future" Canadian-American actor—on the effort to fight the neurodegenerative brain disease second only to Alzheimer's in worldwide prevalence.

The research will use "a new big data analytics platform that detects patterns in participant data collected from wearable technologies used to monitor symptoms," an Intel statement said.

"This effort is an important step in enabling researchers and physicians to measure progression of the disease and to speed progress toward breakthroughs in ."

The statement added that by collecting and analyzing data from thousands of individuals, such as slowness of movement, tremor and sleep quality, researchers can get a better picture of the progression of the disease.

The research will use wearables that "can unobtrusively gather and transmit objective, experiential data in real time, 24 hours a day, seven days a week," according to the statement.

"Nearly 200 years after Parkinson's disease was first described by Dr James Parkinson in 1817, we are still subjectively measuring Parkinson's disease largely the same way doctors did then," said Todd Sherer, chief executive of the foundation.

"Data science and hold the potential to transform our ability to capture and objectively measure patients' actual experience of disease, with unprecedented implications for Parkinson's drug development, diagnosis and treatment."

© 2014 AFP

Citation: Intel to use 'big data' to battle Parkinson's disease (2014, August 13) retrieved 19 March 2024 from https://medicalxpress.com/news/2014-08-intel-big-parkinson-disease.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Blood biomarker could mark severe cognitive decline, quicker progression among Parkinson's patients

 shares

Feedback to editors